uniQure/$QURE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About uniQure
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
Ticker
$QURE
Sector
Primary listing
Employees
209
Headquarters
Website
uniQure Metrics
BasicAdvanced
$3.9B
-
-$3.85
0.13
-
Price and volume
Market cap
$3.9B
Beta
0.13
52-week high
$65.12
52-week low
$5.35
Average daily volume
5.6M
Financial strength
Current ratio
9.982
Quick ratio
9.347
Long term debt to equity
-12,941.469
Total debt to equity
-13,039.121
Interest coverage (TTM)
-2.60%
Profitability
EBITDA (TTM)
-146.439
Gross margin (TTM)
-850.06%
Net profit margin (TTM)
-1,387.98%
Operating margin (TTM)
-1,129.51%
Effective tax rate (TTM)
-0.89%
Revenue per employee (TTM)
$70,000
Management effectiveness
Return on assets (TTM)
-15.38%
Return on equity (TTM)
-427.47%
Valuation
Price to revenue (TTM)
226.427
Price to book
-861.16
Price to tangible book (TTM)
-32.85
Price to free cash flow (TTM)
-18.631
Free cash flow yield (TTM)
-5.37%
Free cash flow per share (TTM)
-3.372
Growth
Revenue change (TTM)
-48.26%
Earnings per share change (TTM)
-34.86%
3-year revenue growth (CAGR)
-38.61%
10-year revenue growth (CAGR)
8.92%
3-year earnings per share growth (CAGR)
16.17%
10-year earnings per share growth (CAGR)
1.84%
What the Analysts think about uniQure
Analyst ratings (Buy, Hold, Sell) for uniQure stock.
Bulls say / Bears say
As of June 30, 2025, uniQure held $377.0 million in cash, cash equivalents and investment securities, which management expects will fund operations into the second half of 2027, materially reducing near-term financing risk. (SEC)
The FDA has aligned with uniQure on the statistical analysis plan and CMC requirements for AMT-130, supporting a planned BLA submission in Q1 2026 and de-risking the regulatory pathway. (GlobeNewswire)
Pivotal Phase I/II 36-month topline data showed high-dose AMT-130 achieved a statistically significant 75% slowing of Huntington’s disease progression versus a propensity-matched external control (p=0.003), meeting its primary endpoint and validating clinical efficacy. (GLOBE NEWSWIRE)
Q2 2025 revenue declined 52.3% year-over-year to $5.3 million, missing consensus and underscoring limited commercial traction outside HEMGENIX® royalties. (GlobeNewswire)
The divestiture of the Lexington manufacturing facility reduced contract manufacturing and collaboration income by $7.1 million and $2.1 million respectively, leaving a narrow revenue base dependent on a single licensed product. (GlobeNewswire)
Acceptance of AMT-130’s accelerated approval pathway remains uncertain due to reliance on external control data and intermediate endpoints, which the FDA could reassess, potentially delaying or derailing BLA approval. (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.
uniQure Financial Performance
Revenues and expenses
uniQure Earnings Performance
Company profitability
uniQure News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for uniQure stock?
uniQure (QURE) has a market cap of $3.9B as of October 16, 2025.
What is the P/E ratio for uniQure stock?
The price to earnings (P/E) ratio for uniQure (QURE) stock is 0 as of October 16, 2025.
Does uniQure stock pay dividends?
No, uniQure (QURE) stock does not pay dividends to its shareholders as of October 16, 2025.
When is the next uniQure dividend payment date?
uniQure (QURE) stock does not pay dividends to its shareholders.
What is the beta indicator for uniQure?
uniQure (QURE) has a beta rating of 0.13. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.